Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Analysts have had mixed feelings about Merck in recent years, with concerns the company, like other big pharmaceuticals, ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 10% in early trading, largely because of weaker ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc.

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...